30.08.2016 • NewsadditivesBASFDede Willams

BASF Global Photoinitiators to IGM Resins

BASF has sold its global photoinitiator business to IGM Resins based in the Netherlands to focus on resin and additive technologies for radiation-curing markets. Financial terms were not disclosed. The German chemical giant said its high-performance photoinitiators dedicated to specific needs of electronics customers are not part of the divestment, as the electronics industry is one of its strategic focus areas.

Business assets including technology, patents and certain trademarks, customer relationships and business-related contracts as well as BASF’s photoinitiator production site in Mortara, Italy, are to be part of the deal, and all employees will transfer to IGM shortly after consultations with local employee representatives are concluded. Some 120 employees are affected globally.

“This transaction allows BASF to focus on its core resins and additives technologies in the radiation-curing markets,” said Markus Kramer, president of the Dispersions & Pigments division, while the same time catering to the specific needs of the electronics industry with high-performance photoinitiators.

Photoinitiators are used in radiation-curing formulations in various industries, with typical end-user applications in coatings for furniture and flooring as well as inks for printing and packaging.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read